Mechanisms of Retinal Ganglion Cell Death in Glaucoma
Principal Investigator
Neeraj Agarwal, PhD
University of North Texas Health Science Center
Fort Worth, TX, USA
About the Research Project
Program
Award Type
Standard
Award Amount
$35,931
Active Dates
April 01, 2000 - March 31, 2002
Grant ID
G2000004
Summary
In a project funded previously by NGR, Dr. Agarwal created a retinal ganglion cell (RGC) line to be used in further research. He is now utilizing the cell line in an in-vitro experiment in which the cells are deprived of a growth factor to see how this affects apoptosis (cell death) in RGCs. His hypothesis is that growth factor deprivation will cause the cells to further decrease the production of autocrine (self-produced) growth factors. He will then attempt to determine if the in vitro model of cell death involves activation of the caspases that are thought to be central to RGC apoptosis in vivo. If the new cell line duplicates the known effects of growth factor deprivation already observed in animals, this cell line will be highly useful for further experimentation on the process of cell death in glaucoma.
Related Grants
National Glaucoma Research
Role of a Key Gene, Angptl7, in Steroid-Induced Glaucoma
Active Dates
July 01, 2025 - June 30, 2027
Principal Investigator
Dan Stamer, PhD
Current Organization
Duke University School of Medicine
Role of a Key Gene, Angptl7, in Steroid-Induced Glaucoma
Active Dates
July 01, 2025 - June 30, 2027
Principal Investigator
Dan Stamer, PhD
Current Organization
Duke University School of Medicine
National Glaucoma Research
Enhancing Access to Glaucoma Care Using Artificial Intelligence
Active Dates
July 01, 2025 - June 30, 2027
Principal Investigator
Benjamin Xu, MD, PhD
Current Organization
University of Southern California
Enhancing Access to Glaucoma Care Using Artificial Intelligence
Active Dates
July 01, 2025 - June 30, 2027
Principal Investigator
Benjamin Xu, MD, PhD
Current Organization
University of Southern California
National Glaucoma Research
Assessment of Vascular Resistance in Glaucoma
Active Dates
July 01, 2025 - June 30, 2027
Principal Investigator
Brad Fortune, OD, PhD
Current Organization
Legacy Devers Eye Institute
Assessment of Vascular Resistance in Glaucoma
Active Dates
July 01, 2025 - June 30, 2027
Principal Investigator
Brad Fortune, OD, PhD
Current Organization
Legacy Devers Eye Institute